Luc Dochez, PharmD, is a managing partner at DROIA Genetic Diseases and a partner at DROIA Oncology Ventures. He is a (co)-founder of biotech companies such as Montis Biosciences, Pharvaris, and Vico Therapeutics. He was CEO of Tusk Therapeutics from May 2015 until its acquisition by Roche in September 2018. He joined Tusk from Prosensa Holding N.V. where he served as chief business officer and senior vice president of business development for seven years until its acquisition by BioMarin Pharmaceutical Inc. Earlier in his career, Luc served as vice president of business development at TiGenix, director of business development at Methexis Genomics, and a consultant at Arthur D. Little.

Luc holds a PharmD degree and a postgraduate degree in business economics from the University of Leuven (Belgium) and an MBA from Vlerick Management School (Belgium). Luc serves on the boards of directors of Erytech, Vico Therapeutics, Montis Biosciences, Volastra, and QurAlis.